Voronoi, Inc.
Research Voronoi, Inc. (310210.KQ) on Bullrun: market cap KRW 2.26T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker310210.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 2.26T
- Financial periodQ2 2026
- Net income-KRW 29.02B
- Free cash flow-KRW 25.69B
Valuation Snapshot
latest market cap is KRW 2.26T.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 2.26T | n/a | n/a | n/a |
Dividend history
About Voronoi, Inc.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Voronoi, Inc.'s market cap?
Voronoi, Inc.'s market capitalization is KRW 2.26T.
What does Voronoi, Inc. do?
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis.